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Homocystinuria: what about mild 
hyperhomocysteinaemia?
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Summary
Hyperhomocysteinaemia is asso­
ciated with an increased risk of 
atherosclerotic vascular disease 
and thromboembolism, in both 
men and women. A variety of 
conditions can lead to elevated 
homocysteine levels, but the rela­
tion between high levels and vas­
cular disease is present regardless 
of the underlying cause. Pooled 
data from a large number of 
studies demonstrate that mild 
hyperhomocysteinaemia after a 
standard methionine load is pre­
sent in 21% of young patients with 
coronary artery disease, in 24 % of 
patients with cerebrovascular dis­
ease, and in 32% of patients with 
peripheral vascular disease. From  
such data an odds ratio of 13*0 
(95% confidence interval 5.9 to 
28.1), as an estimate of the relative 
risk of vascular disease at a young 
age, can be calculated in subjects 
with an abnormal response to 
methionine loading. Further­
more, mild hyperhomo-cystei- 
naemia can lead to a two- or 
three-fold increase in the risk of 
recurrent venous thrombosis. Ele­
vated homocysteine levels can be 
reduced to normal in virtually all 
cases by simple and safe treatment 
with vitamin B6, folic acid, and 
betaine, each of which is involved 
in methionine metabolism. A 
clinically beneficial effect of such 
an intervention, currently under 
investigation, would make large- 
scale screening for this risk factor 
mandatory.
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Atherosclerotic disease, notably coronary artery disease, remains the major 
cause of death in the western world. This increased risk of mortality from 
cardiovascular disease cannot be fully explained by traditional risk factors such 
as hyperlipoproteinaemia, smoking, hypertension and male sex. Since the last 
decade, mildly elevated homocysteine levels have also been recognised as a 
serious risk factor in the development of atherosclerotic disease and 
thromboembolism.
Severe hyperhomocysteinaemia, such as in homocystinuria due to cystathio­
nine synthase deficiency, is inherited as an autosomal recessive trait and may 
lead to occlusive arterial disease and thromboembolism even in early infancy.1 
From a collaborative study on more than 600 homozygous patients, Mudd et al 
observed that there was a 50% chance for untreated patients to suffer from a 
vascular event before the age of 30 years.2 In line with this observation, the 
hypothesis has been put forward that even mild hyperhomocysteinaemia may 
predispose for arterial occlusive disease, even at a young age. Indeed, case- 
controlled, cross-sectional, and prospective epidemiological studies have shown 
that mildly elevated homocysteine levels are associated with an increased risk of 
arterial occlusive disease.3" This relationship has been reported for both fasting 
homocysteine levels and for hyperhomocysteinaemia unmasked by means of a 
methionine loading test in which homocysteine metabolism is stressed with an 
oral dose of L-methionine (0.1 g/kg body weight). Whether fasting or post­
methionine plasma homocysteine level is the better predictor of vascular disease 
has not been clarified.
It has been shown that safe doses of vitamins can induce normalisation of 
such increased homocysteine blood levels4,5 and may ameliorate endothelial 
function in mildly hyperhomocysteinaernic vascular patients.8 In conclusion, 
mild hyperhomocysteinaemia has been recognised as an important risk factor 
for atherosclerotic disease, thus providing the rationale for large-scale screening 
and intervention with innocuous vitamins in patients with elevated homocyst­
eine levels. Relevant aspects of this unconventional risk factor are briefly 
discussed in this paper.
4
Metabolism and aetiology of hyperhomocysteinaemia
The essential amino acid methionine, which is present in protein of animal 
origin, is the only source of homocysteine in man,1 Normally, homocysteine is 
rapidly catabolised by transsulphuration into cysteine or is remethylated to 
methionine (figure 1). Cystathionine synthase catalyses the first step in 
transsulphuration with vitamin B6 in its active form, pyridoxal phosphate, as 
cofactor. In many body tissues remethylation by the folate- and vitamin B12-
C
dependent enzyme N -methyltetrahydrofolate-homocysteine methyltransferase 
is operational and in the liver homocysteine is also remethylated by betaine 
(trimethylglycine), formed from choline.
Plasma homocysteine is the sum of homocysteine, whether free or bound to 
proteins, and the homocysteinyl moieties of the disulphides homo cystine and 
cysteine-homocysteine. Hyperhomocysteinaemia refers to levels of such 'total5 
homocysteine level in the blood, plasma or serum. Epidemiological studies 
strongly suggest a graded response rather than a threshold effect of 
homocysteine levels, but for practical reasons the following classification has 
been made: moderate, intermediate and severe fasting hyperhomocysteinaemia, 
with levels between 16 and 30> 31 and 100, and more than 100 fimol/1, 
respectively.9 In diagnosing hyperhomocysteinaemia in the individual patient it 
is preferable to perform a methionine loading test10’11, as stated later. The 
generally used cut-off points for post-load hyperhomocysteinaemia are sex 
specific, ie, in men 54, in premenopausal women 51, and in postmenopausal 
women 69 /imol/1, respectively.10,11
Severe hyperhomocysteinaemia, also' known as homocystinuria, is an
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Prevalence of mild
(post-load) hyperhomo­
cysteinaemia
• 1-2% in the general population3
Among 730 screened vascular patients:
• 25-33% of those with peripheral 
arterial disease4,5
• 20-28% of those with 
cerebrovascular disease4,5
• 15 % of those with coronary artery 
disease4
Box 2
Diagnosis
• elevated homocysteine levels in the 
fasting state^  and/or
• after methionine loading (0.1 g/kg 
orally)
Box 3
contribute to the accelerated development of macroangiopathy in diabetics. 
These findings should therefore be considered in the context of a positive 
relation between homocysteine and creatinine.
The intra-individual day-to-day variation in fasting homocysteine levels is 
rather wide, up to 25%. One of the causes of this variation could be dietary 
changes during the day preceding die fasting samplings because it has been 
shown that a protein-rich meal may affect plasma homocysteine levels for at 
least eight hours.23 A post-methionine-load homocysteine determination, four 
to six hours after the methionine intake, will have a distance in time from the 
last protein-containing meal of at least 16 hours and during the test itself the 
protocol inhibits protein intake. Therefore., less intra-individual variation in 
post-methionine plasma homocysteine levels might be expected (box 1).
The antifolate drug methotrexate, folate-deficiency-inducing anti-epileptics, 
and nitrous oxide, which inactivates vitamin Bi2y will increase plasma 
homocysteine (box 1). Recently, the modulation of plasma homocysteine by 
these and various other pharmacological agents, such as penicillamine and 
oestrogens, has been extensively reviewed.20,24
Mild hyperhomocysteinaemia and vascular disease
In 1976, Wilcken and Wilcken were the first to publish results suggesting that 
even mild hyperhomocysteinaemia could have a possible role in the pathogen­
esis of coronary artery disease.25 They showed that about 30% of young patients 
with angiographically proven coronary artery disease demonstrated mild 
hyperhomocysteinaemia, four hours after a methionine load. This unique 
finding suggested an important role for even mild hyperhomocysteinaemia in 
the pathogenesis of vascular disease at a young age. Since then, numerous 
studies have shown that mild hyperhomocysteinaemia is a frequent finding 
amongst vascular patients. In 1992 pooled data revealed a prevalence of 32% in 
patients with peripheral vascular disease, 24% in patients with cerebrovascular 
disease, and 21% in patients with coronary artery disease,3,26 From pooled data 
an odds ratio of 13.0 (95% Cl 5.9-28.1) could be calculated as an estimate of 
the relative cardiovascular risk in subjects with an abnormal response to 
methionine loading compared to normal responders.3
The recently published data by van den Berg et a t and Franken et aP are in 
line with the finding of high prevalences of mild post-load hyperhomocystei­
naemia amongst vascular patients (box 2). Recently, prospective studies have 
indeed confirmed that mild hyperhomocysteinaemia in men is associated with 
an increased incidence of myocardial infarction6,7 and, possibly, of stroke.27 In 
addition, a dose-response relationship is supported by the fact that hyperho­
mocysteinaemia is reported to be associated with the severity of peripheral 
arterial disease28 and with the number of stenosed coronary vessels29 in 
arteriosclerotic patients. Malinow et a/30 observed a graded increase in the 
prevalence of carotid artery intimal-medial thickening with increasing random 
homocysteine levels in asymptomatic subjects, which was more pronounced in 
women. Selhub et a t1 reported a relationship between random homocysteine 
levels and the prevalence of carotid artery stenosis. Taken together, the 
epidemiologic evidence may indicate a graded effect of plasma homocysteine 
levels, as in hypercholesterolaemia, rather than a threshold effect.
It has recently been shown that mild hyperhomocysteinaemia is a strong risk 
factor for recurrent venous thrombosis and can lead to a two-fold or three-fold 
increase in risk.32 Possible relationships between plasma homocysteine and 
convential risk factors for vascular disease have been studied but no such 
relation was established for tobacco smoking, hypertension, serum lipids, or 
diabetes mellitus. Therefore, so far, hyperhomocysteinaemia seems to be an 
independent risk factor for cardiovascular disease.12,33
At this stage, it is unresolved which is the most sensitive indicator of excess 
cardiovascular risk, either the fasting, the post-load homocysteine level, or both 
(box 3). Identification of patients at risk simply on the basis of their fasting 
homocysteine level might be insufficient because, depending on the cut-off 
point, about 40-54% of patients with high post-methionine homocysteine have 
a normal fasting level.4,10 The latter finding, moreover, suggests the existence 
of multiple underlying metabolic deficits, because fasting and post-methionine 
homocysteine levels are thought to be determined by different pathways, ie, 
remethylation and transsulphuration of homocysteine, respectively. A serious 
argument against the use of the post-methionine homocysteine level as the 
criterion of hyperhomocysteinaemia is the fact that the methionine loading test 
is too laborious and expensive to include in the design of epidemiological 
studies with large numbers of participants. Even in diagnostic procedures in 
individual vascular patients, the practical concerns and high costs of establish-
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Atherogenetic mechanisms 
of homocysteine
• damaging endothelial cells by 
generation of hydrogen peroxide, 
oxidation of low-density lipoprotein, 
and depletion of nitric oxide
o proliferation of smooth muscle cells
•  coagulation/fibrinolysis interaction: 
inhibiting expression of 
thrombomodulin
Box 4
ing post-methionine homocysteine levels suggest that this test is not feasible as 
a routine screening procedure. If it is to become so, more effort is needed to 
standardise the sampling of fasting homocysteine levels and more attention 
should be paid to die food intake on the day preceding the blood sampling, to 
minimise the wide intra-individual daily variation of these levels, as mentioned
before.
Pathogenesis of vascular disease in mild hyperhomocysteinaemia
Homocysteine, an amino acid with a free sulphhydryl group, is generally held to 
be atherogenic and thrombogenic, although die exact pathophysiological 
sequence has not been clarified. Homocysteine is thought to damage 
endothelial cells by several mechanisms, eg, generation of hydrogen peroxide34 
oxidation of low-density lipoproteins, and depletion of nitric oxide-mediated 
detoxification of homocysteine.35 In studies in animals, high homocysteine 
levels have been shown to induce endothelial cell injury.36,3 In vitro studies 
indicate that cultured endothelial cells from obligate heterozygotes for 
homocystinuria are more susceptible to homocysteine-mediated injury than 
normal cells.38 Another potential mechanism, recently described by Tsai et a/39 
is that homocysteine induces the proliferation of smooth muscle cells, a key 
feature of atherogenesis. It has also been reported that homocysteine inhibits 
the expression of thrombomodulin on the surface of the endothelial cell, leading 
to decreased protein C activation and thus, possibly, contributing to the 
development of thrombosis in hyperhomocysteinaemic patients.40
Although data in humans are scarce, van den Berg et a t showed in 
hyperhomocysteinaemic patients with lower extremity occlusive atherosclerotic 
disease that endothelial dysfunction, as estimated by increased plasma von 
Willebrand factor concentrations, was ameliorated by treatment of hyperho­
mocysteinaemia with folic acid and vitamin B<,.
In conclusion, abnormalities of endothelial cells, platelets, clotting factors, 
serum lipids or disorders in the complex interaction of these factors have been 
held responsible for the vascular damage and thrombogenesis. A survey of all 
proposed hypotheses has been presented elsewhere (box 4).1,1
The cause of mild hyperhomocysteinaemia in vascular patients
Analogous to the first observation by Sardharwalla et al of mildly elevated
homocysteine levels in obligate heterozygotes for cystathionine synthase
deficiency,41 it has been proposed that such hyperha mocysteinemia detected
in vascular patients also originates from heterozygosity for this specific enzyme
defect. In the two reports presenting determinations of cystathionine synthase
activity in cultured fibroblasts from hyperhomocysteinaemic vascular patients,
1 1 1
an intermediate enzyme deficiency was indeed found. In recent years, 
however, it has become increasingly clear that the identification of patients with 
vascular disease as heterozygotes for cystathionine synthase deficiency is not 
convincing.42,43 More recent determinations of enzyme assays in hyperhomo- 
cysteinaemic vascular patients show that cystathionine synthase activity is 
deficient only in sporadic cases and wide variability in activity in cultured 
fibroblasts may occur, even in healthy persons12 and recently it has been shown 
that heterozygous carriers and homocystinuric patients were free from 
inactivating mutations.44
The role of the cystathionine synthase gene may have been overestimated in 
the past and, therefore, the re-methylation pathway has gained more interest in 
recent years. Recently, Rozen’s group cloned the gene responsible for the 
enzyme methylenetetrahydrofolate reductase, which has permitted mutational 
analysis in this gene, facilitating the evaluation of the re-methylation pathway in 
the aetiology of hyperhomocysteinaemia.46 Thermolability of 5,10 methylene­
tetrahydrofolate reductase proves to be a far more common genetic defect 
among these patients.14,42 Homozygotes for this mutation have been detected 
in 5% of the general population and in up to 17% of 212 coronary patients,15 
Recently, a common mutation in 5,10-methylenctetrahydrofolate reductase has 
been identified, which in the heterozygous or homozygous state correlates with 
reduced enzyme activity and decreased thermostability in lymphocyte 
extracts.46 In addition, individuals homozygous for the mutation have 
significantly elevated plasma homocysteine levels, botii in the fasting state 
and after methionine loading.46 Notwithstanding the occurrence of thermo- 
labile enzyme in 28% of some groups of hyperhomocysteinaemic vascular 
patients ,4~ this prevalence still does not seem high enough to predict a 
predominant role of this defect among possible causes of mild 
hyperhomocysteinaemia in vascular patients.
Mild hyperhomocysteinaemia and vascular disease
%
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T reatment
In fasting homocysteine
folic acid: 0.65 mg daily: 40% reduction
2.5 mg daily: 37% reduction
5 mg daily: 50% reduction
10 mg daily: 50% reduction 
vitamin B6: no effect
vitamin B]2: only modest effect (-15%), but should be added to avoid folic acid
refractoriness and deterioration of neuropathy in vitamin B 12- 
deficient cases. A sufficient dose is 0.4 mg daily
In post-methionine hyperhomocysteinaemia 
vitamin B6j 100 mg + folic acid, 5 mg daily: 50% reduction 
vitamin B6, 100 to 250 mg daily: 40% reduction
folic acid (n = 6 patients only): 45% reduction
(lower doses of vitamin B6 and/or folic acid have not been studied)
To lower fasting homocysteine levels
0.65 mg folic acid plus 0.4 mg cyanocobalamin
To lower post-methionine homocysteine levels 
100 mg vitamin B6 plus 5 mg folic acid
Box 5
Homo cysteine-lowering interventions
FASTING HOMOCYSTEINE LEVELS
From pooled data11 it can be estimated that it is possible to induce a reduction 
of about 40% of mildly elevated fasting plasma homocysteine levels by the use 
of doses of folic acid as low as 0.65 mg daily. A lower dose has not been studied. 
A dose of 2.5 mg daily had the same effect as 0.65 mg3 5 mg daily resulted in a 
slightly larger decrease of about 50%3 and increasing the dose up to 10 mg daily 
had no extra effect. Supplementation of vitamin B6 did not affect fasting 
homocysteine levels significantly. Vitamin Bi2 in an oral dose of 0.4 mg 
cyanocobalamin daily has only a modest effect but is added to folic acid therapy 
mainly to avoid folic-acid refractoriness in the case of vitamin Bi2 deficiency 
and to prevent the development of neuropathy due to unrecognised pernicious 
anaemia (box 5). In summary, the prescription of 0.65 mg folic acid plus 0.4 mg 
cyanocobalamin daily is sufficient to lower a mild fasting hyperhomo­
cysteinaemia by about 50%.
POST-METHIONINE HOMOCYSTEINE LEVELS
Available data on the effect of various homocysteine-lowering regimens upon 
mildly elevated post-methionine homocysteine levels 5 show that the use of 100 
mg vitamin B6 plus 5 mg folic acid decreases homocysteine levels by about 
50%. Vitamin B6 as a single agent in doses from 100 to 250 mg daily resulted in 
a slightly lower reduction of about 40%. Folic acid as the sole therapy has been 
studied in only six patients so far and showed a 45% decrease in these patients. 
The efficacy of lower doses of vitamin B6 and/or folic acid as a single or 
combined therapy has not been explored. Remarkably  ^only the combination of 
vitamin B6 plus folic acid resulted in normalisation of post-methionine 
homocysteine levels in 90% or more of the treated patients^  whereas the 
respective single treatments did much less3 ie3 about 50% (box 5). In summary3 
100 mg vitamin B6 and 5 mg folic acid daily should be prescibed for the 
treatment of post-methionine hyperhomocysteinaemia.
Conclusions
The prevalence of mild hyperhomocysteinemia in young patients with arterial 
occlusive disease is high and hyperhomocysteinaemia has to be accepted as a 
serious risk factor for vascular disease. Future studies will hopefully elucidate in 
which way atherosclerosis and thromboembolic events are induced in patients 
with hyperhomocysteinaemia. Furthermore  ^ simple and inexpensive therapy 
with innocuous vitamins can normalise homocysteine metabolism, as assessed 
by the homocysteine plasma level before and after methionine loadings in 
virtually all these patients. Intervention studies are needed to clarify if such 
treatment will also reduce morbidity and mortality. The demonstration of a 
clinical benefit of homocysteine-lowering interventions would be required to
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Learning points
© mild hyperhomocysteinaemia is a risk factor for atherosclerotic disease and venous 
thrombosis
« a methionine loading test is recommended for the diagnosis of 
hyperhomocysteinaemia in the individual patient 
® in the case of an abnormal test result, treatment with vitamins involved in 
homocysteine metabolism should be considered
Box 6
justify routine screening for this risk factor on a large scale. Meanwhile, to 
clarify the individual patient’s risk of developing ariierosclerosis or thromboem­
bolic events^  it is advisable to perform a methionine loading test for the 
screening of hyperhomocysteinaemia5 at least in those cases in which 
conventional risk factors are absent (box 6).
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